ArticleGynecologic oncology reports2026
Acceptance of weight loss medication in patients with atypical hyperplasia or carcinoma of the endometrium as part of the fertility preservation treatment: A qualitative study.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Sustained weight loss in combination with progestin may improve oncologic and fertility outcomes for young patients with endometrial cancer/atypical hyperplasia (EC/AH) desiring fertility-preserving treatment. Weight-loss medications are non-invasive and effective weight management tools; however, their acceptability is unknown in this population. Thus, we conducted a qualitative study to understand the acceptability of weight loss medication in young patients with obesity and EC/AH. Methods: Purposive sampling was used to recruit patients between 18 and 41 years of age with body mass index (BMI) ≥ 27, and a diagnosis of grade 1 endometrioid EC or AH. Semi-structured interviews were conducted to explore participants' perception of their weight, its relationship to their EC/AH diagnosis, and their acceptability of weight-loss medication as part of fertility-sparing treatment. Results: Thirteen interviews were conducted. The median participant age was 37 years (26-40), and the median BMI was 34.8 (28-48). Participants lacked understanding of the relationship between obesity, EC/AH, and infertility. Participants identified the need for honest, early, actionable, and sensitive obesity counselling in the context of EC/AH management. Participants were receptive to the use of weight-loss medication and expressed little worry about associated stigma; however, they were highly concerned about cost, side effects, and sustainable weight loss, and emphasized that addressing these concerns would be essential to increase their comfort. Conclusions: Weight-loss medication may be an acceptable adjunct to progestin treatment in this population, if preceded by a thorough risk-benefit discussion and early counselling on the role and management of obesity in EC/AH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.